JAMIA Open is an open-access journal dedicated to advancing the field of health informatics, published by Oxford University Press. Since its inception in 2018, the journal has provided a platform for novel research, reviews, and case studies that bridge the gap between healthcare and information technology. With an impressive impact factor and a current classification in the Q2 quartile for Health Informatics, JAMIA Open has established itself as a vital resource for researchers and practitioners alike, facilitating the dissemination of innovative findings that contribute to the evolution of healthcare systems. Based in the United States, the journal is committed to providing free and equitable access to high-quality research, thus promoting a collaborative and informed approach to tackling pressing health issues. As it continues to grow and evolve, JAMIA Open remains a cornerstone in the landscape of health informatics, appealing to a diverse audience of researchers, professionals, and students looking to inspire change in their fields.

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

PSYCHO-ONCOLOGY is a leading international journal published by Wiley, focusing on the interdisciplinary fields of psychology and oncology. Established in 1992 and continuing its impactful contributions to academic discourse through 2024, the journal occupies a prestigious position with a Q1 ranking in Experimental and Cognitive Psychology and notable placements in both Oncology and Psychiatry and Mental Health categories. With an impressive Scopus ranking that places it in the 86th and 76th percentiles within its respective fields, PSYCHO-ONCOLOGY facilitates the exploration of psychological dimensions of cancer and its treatment, emphasizing evidence-based research that greatly informs clinical practices. Researchers, professionals, and students benefit from its comprehensive scope, which encompasses mental health implications linked to cancer diagnosis, treatment, and survivorship. Although it operates on a subscription model, the journal remains a vital resource for advancing knowledge and promoting psychosocial well-being in oncology, making it an essential read for those dedicated to improving patient outcomes.

The Journal of Cancer Survivorship, published by SPRINGER, serves as a premier platform for research dedicated to the complex realities faced by cancer survivors. Established in 2007, this esteemed journal focuses on the multifaceted aspects of oncology care, particularly within the nursing domain, reflecting its significance with a 2023 Q1 ranking in both Oncology and Oncology (nursing) categories. Additionally, it boasts impressive Scopus rankings, positioning it in the top tier of nursing and oncology fields. Targeted towards researchers, healthcare professionals, and students, the journal emphasizes advancements in survivorship care, psychosocial support, and health-related quality of life post-cancer treatment. With no open access option, the journal maintains a high standard of scholarly communications while ensuring rigorous peer review processes, making it an indispensable resource in the evolving landscape of cancer survivorship studies.

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

Digital Health is a pioneering open-access journal published by SAGE Publications Ltd, dedicated to advancing the field of health technology and its intersection with health policy, informatics, and the broader medical landscape. Since its inception in 2015, the journal has rapidly established itself as an essential resource for researchers, professionals, and students, serving as a platform for innovative research that leverages digital tools to improve health outcomes. Currently ranked in the Q2 category across four relevant domains, including Computer Science Applications and Health Informatics, it commands respect within the academic community. With its accessible framework, Digital Health facilitates the dissemination of critical findings and new methodologies that inform policy and practice. The journal’s commitment to open access promotes worldwide access and cooperation, making significant contributions to the evolving landscape of digital health.

The JOURNAL OF CANCER EDUCATION, published by SPRINGER, stands as a pivotal resource in the fields of oncology and public health. With an ISSN of 0885-8195 and an E-ISSN of 1543-0154, this esteemed journal has been disseminating vital research since 1986 and continues to play a crucial role in advancing knowledge until 2024. Recognized in 2023 with a Q3 rating in Oncology and a Q2 rating in Public Health, it reflects a solid standing in an ever-evolving academic landscape. The journal ranks #297 out of 665 in the Public Health category and #233 out of 404 in Oncology, showcasing its contribution to the scientific community. Aimed at researchers, practitioners, and students alike, the journal invites submissions that enhance understanding of cancer education, prevention, and management, ensuring that the knowledge shared is both impactful and accessible. With its focus on evidence-based practices and innovative educational strategies in cancer care, the JOURNAL OF CANCER EDUCATION serves as an essential platform for fostering collaboration and progress in oncology education.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.